Harbin Pharmaceutical Group

Harbin Pharmaceutical Group, listed on the Shanghai Stock Exchange since 1993, is a major player in the pharmaceutical industry with a focus on chronic diseases, oncology, and cardiovascular drugs.

Company Overview

Harbin Pharmaceutical Group, listed on the Shanghai Stock Exchange since 1993 under stock code '600664', is a prominent player in the pharmaceutical industry. The company operates eight major production bases and holds approximately 1800 drug approvals. With a workforce of over 1000 R&D technical staff, Harbin Pharmaceutical Group is well-equipped to lead advancements in healthcare.

Product Range

Harbin Pharmaceutical Group offers a wide and diverse range of products. The company's portfolio includes over-the-counter drugs, prescription medications, and health supplements. Notable products include zinc gluconate oral solution, compound calcium gluconate oral solution, and amoxicillin capsules, catering to various health needs.

Focus on Therapeutic Areas

Harbin Pharmaceutical Group focuses on pioneering innovations in treating chronic diseases, oncology, and cardiovascular conditions. The company's dedication to these areas is illustrated through its substantial investment in research and development, aimed at improving patient outcomes and healthcare solutions.

R&D and Technical Workforce

With over 1000 R&D technical staff, Harbin Pharmaceutical Group places significant emphasis on research and development. This skilled workforce supports the company's mission to innovate and offer effective pharmaceutical solutions across various therapeutic areas. The company’s comprehensive approach to R&D ensures the continual improvement and expansion of its product lineup.

Brand Value and Trademarks

Harbin Pharmaceutical Group's brand strength is underscored by its ownership of five well-known trademarks within China and a brand value that exceeds 20 billion yuan. These trademarks signify the company's prominence and influential presence in the pharmaceutical market.